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orphological Subtypes by Echocardiography
nd Cardiac Magnetic Resonance Imaging
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. Jamil Tajik, MD, FACC‡
YPERTROPHIC CARDIOMYOPATHY (HCM) can be deﬁned as myocardial hypertrophy
n the absence of a causative condition and is thought to emanate from genetic mutations that result
n alterations in the cardiac myoﬁlament. Hypertrophic cardiomyopathy is characterized by marked
enotypic, phenotypic, and clinical heterogeneity. Ventricular septal hypertrophy is the most common
orm of hypertrophy with mid-ventricular and apical forms of hypertrophy being far less common. The
attern of ventricular septal hypertrophy is variable and can broadly be divided into the followingorphological subtypes: reverse curvature, sigmoid, and neutral.
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myosin.ppropriate identification of these morphological
ubtypes may be helpful because they appear to be
losely related to the presence or absence of a
CM-related genetic abnormality. In a recent
tudy, the majority of patients (79%) with reverse
urvature septum HCM harbored an identifiable
CM-associated mutation, whereas only a small
roportion of patients (16%) without a reverse cur-
ature septum were genotype positive (1). Table 1
emonstrates the reported relative frequency of gene
bnormalities in different HCM septal morphologic
ubtypes (1). These data have significant implica-
ions with respect to genetic counseling and the
linical application of genetic testing. Specifically,
he possibility of echocardiography-guided genetic
esting in HCM is evident. Furthermore, other
iagnostic modalities such as cardiac magnetic res-
nance imaging are helpful in delineating different
henotypic expressions of HCM (2). When using
he delayed enhancement technique, magnetic reso-
ance imaging also allows for the detection of myocar-rom the *Division of Cardiovascular Diseases and the †Department o
he ‡Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arial fibrosis, which has been demonstrated to be
ssociated with other high risk markers for sudden
ardiac death in HCM patients (3). Echocardiographic
nd magnetic resonance imaging examples of each
CM morphologic subtype are shown in Figure 1.
Table 1. Frequency of Genetic Mutations in HCM by Septal
Characteristics Reverse Sigmoid Neutral
Genotype positive (%) 79 8 41
Family history of HCM (%) 45 21 34
Family history of SCD (%) 19 10 16
Type of mutation
None (%) 21 92 59
MYBPC3 (%) 34 5 19
MYH7 (%) 29 2 13
MYL2 (%) 4 0 3
TNNT2 (%) 3 1 0
TNNI3 (%) 2 1 3
TPM1 (%) 2 0 0
ACTC (%) 1 0 0
Multiple mutations (%) 5 0 3
ACTC  actin; HCM  hypertrophic cardiomyopathy; MYBPC3  myo
protein C; MYH7  myosin heavy chain; MYL2  myosin light chain; SCD
cardiac death; TNNI3  troponin I; TNNT2  troponin T; TPM1  -tropoContour
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378Figure 1. HCM Subtypes Imaged by Echocardiography
Upper images: Hypertrophic cardiomyopathy (HCM)
morphologic subtypes are demonstrated by echo-
cardiography. End-diastolic (left) and end-systolic (right)
images of the heart are shown.
Lower images: The HCM subtypes are well demonstrated
by magnetic resonance imaging in the same patients.
Left and middle columns show steady-state free
precession images of the heart in a 3-chamber
orientation in end-diastole and end-systole, respectively.
Right column shows myocardial delayed enhancement
(MDE) images using an inversion recovery gradient-
recalled-echo technique.
(A) Reverse curvature septum HCM shows a predominant
mid-septal convexity toward the left ventricular (LV) cav-
ity with the cavity itself often having an overall crescent
shape. Dynamic subaortic obstruction is present in this
example with systolic anterior motion (SAM) of the mitral
leaﬂets and turbulent ﬂow in the outﬂow tract. Promi-
nent foci of MDE that indicate myocardial ﬁbrosis are
present in the anteroseptum and inferoseptum.
(B) Sigmoid septum HCM shows a generally ovoid LV
cavity with the septum being concave to the LV cavity
and a prominent basal septal bulge. Subaortic obstruc-
tion is present in this example with SAM of the mitral
leaﬂets and a posteriorly directed jet of mitral regurgita-
tion. A small amount of MDE is seen in the septum.
(C) Neutral septum HCM shows an overall straight sep-
tum that is neither predominantly convex nor concave
toward the LV cavity. Subaortic obstruction is present in
this example. A small focus of MDE is seen in the
septum.
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379Figure 1 Continued.
(D) Apical HCM shows a predominant apical distribution of
hypertrophy. Myocardial delayed enhancement is seen in
the LV apex at the site of maximal hypertrophy in this
example.
(E) Mid-ventricular HCM shows predominant hypertrophy
at the mid-ventricular level. In this example, a thinned and
dyskinetic apical pouch is also present. Obstruction is at
the level of the papillary muscles, where turbulence was
identiﬁed. No mitral SAM. Myocardial delayed en-
hancement is seen in the dyskinetic apical pouch.E F E R E N C E S
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